Years Of Experience In Industry Research Articles

Challenges of industrial wastewater treatment: utilizing Membrane bioreactors (MBRs) in conjunction with artificial intelligence (AI) technology

ABSTRACT In the past, decisions on wastewater treatment methods have predominantly rested on expert opinions, utilizing the Delphi method. Yet, with an anticipated increase in diversification and customization, especially in the “small-batch and diverse” market over the next decade, addressing the formulation and execution of wastewater treatment for these non-traditional production processes will present substantial challenges. Relying solely on Delphi experts’ decision-making within a short and time-constrained production planning window is expected to prove inadequate. Predominantly relies on the authors’ over 15 years of industry experience in wastewater treatment, this perspective paper proposes an inventive solution that integrates Membrane Bioreactors (MBRs) with Artificial Intelligence (AI) applications. This approach signifies a more advanced method for industrial wastewater treatment compared to conventional methods, with the intention of garnering increased interest for future research endeavors.

Preparing Property Graduates for the Digital Age: Challenges and Strategies from the Perspective of Australian Property Educators

The work readiness of property graduates is the subject of global discourse and is an increasingly critical gap as employers demand professionals with competencies in their fundamental roles and digital technologies. Although these issues have been explored from the perspectives of students, graduates, and employers, the insights of property academics remain unexplored. As such, this study delved into the challenges encountered by property academics in Australia concerning the training of property graduates for the digital age, as well as the efficacy of strategies used to achieve this. The opinions of 22 property academics were gathered through an online questionnaire survey and analysed through mean scores, relative importance index (RII), and exploratory factor analysis (EFA). The profile of respondents suggests that approximately half of them have no more than five years of industry experience, and only 54.5% currently engage with the industry. The most significant challenges include limited funding to procure bespoke software and insufficient time to achieve digital competency. Furthermore, academics cited limited support from the universities as a key challenge, but rated curriculum rigidity as non-pertinent. Regarding strategies, retraining academics for digital proficiency, increased technical support from universities, adopting active learning, and revising curricula to incorporate digital technology are critical. Collaboration with industry partners and increased funding for software procurement also emerged as key external factors. Variations in these perceptions also suggest that older academics are less receptive towards retraining, academics with more industry experience believe that a restructuring of the curricula is required, and smaller institutions require more funding and industry support. The core themes of the proposed strategies also indicate that holistic curricula integration is required to incorporate the perspectives of all stakeholders. Practically, these findings underscore the pivotal role of academics in bridging the skills gap and the interconnected roles of graduates, universities, and industry partners.

Effectiveness of Water-Amine Combined Process for CO2 Extraction from Biogas

Abstract The EU countries are implementing biomethane production projects from biogas, supplying it to the natural gas distribution grid, or using it as motor fuel. It is also extremely relevant for Ukraine, supposing the problems with gas import due to Russian aggression. Biogas production from landfills, agriculture waste, and sewage is already implemented in Ukraine, so the next step must be biomethane production on an industrial scale and the selection of biogas separation technology is important. Using 11 years of industrial experience in biogas production from landfills, wide experience of the different methane-containing gases separations, and small companies’ industrial possibilities, the most applicable separation technologies for Ukraine were selected: amine, water, and combined water amine carbon dioxide separation. These technologies had compared using computer simulation with real landfill biogas flow rate debt. Results of a software simulation of the most applicable water-amine absorption technology were verified using a laboratory setup. For carbon dioxide concentration in biogas at 32–42 % vol., the specific energy consumption when using water absorption is on average 2 times less compared to amine absorption, but at the same time, the loss of methane due to its solubility in water during water absorption amounted to 7.1–7.6 %, with practically no losses in amine absorption, and minor losses at 0.17–2.8 % in combined water-amine technology. The energy consumption of combined water-amine absorption is comparable to that of water absorption due to: a) reduction of heat losses for the regeneration process of saturated amine absorbent, as part of carbon dioxide has already been removed with water technology; b) using the methane excess to compensate power consumption of the biogas compressor during the preliminary water absorption of carbon dioxide and/or to compensate heat costs of the saturated amine absorbent regeneration

CEO's industry experience and emerging market SME performance: The effects of corruption and political uncertainty

We examine how Chief Executive Officer (CEO) industry-specific experience influences firm performance in small and medium enterprises (SMEs) in emerging markets. Drawing on the upper echelons perspective and learning theory, we propose an inverted U-shaped relationship between an SME CEO's industry-specific experience and firm performance. We also argue that country corruption and political instability moderate this relationship, resulting in lower performance for SME CEOs with little industry experience or many years of industry experience in countries with high corruption or political instability. We test our hypotheses using data from the World Bank's Enterprise Survey of firms in emerging economies from 2006 to 2019. The results support our hypotheses that corruption and political instability primarily hurt the performance of SMEs with CEOs having very long industry experience. We discuss implications of this research for scholars studying SMEs in lesser-developed institutional environments and how leaders may influence SME performance.

The state of practice in soil-structure interaction modelling in New Zealand

The current state of practice in soil-structure interaction (SSI) modelling in New Zealand was investigated through an industry-wide questionnaire. This used a mixed methods, sequential explanatory research design involving the collection of quantitative and qualitative questionnaire data, as well as follow-up focus groups. Several statistically significant relationships were observed for SSI modelling approaches between different engineering fields, company sizes, and years of experience. The key findings from this study suggest that there is no consensus on the best SSI analysis methods, modelling strategies, or guidelines to be used. Overall, fixed base analysis remains the most popular method across all company sizes and number of years of industry experience. Engineers from large companies reported higher consideration for SSI modelling and use of performance-based design for design projects, which perhaps reflects the scale and complexity of projects carried out in those companies. However when SSI is considered, analyses are typically limited to nonlinear vertical springs under the foundation as part of a dynamic analysis. Use of SSI for buildings is typically limited to seismic assessments and complex or otherwise high importance structures. However, bridge engineers routinely used pushover analyses with linear and nonlinear springs and dynamic analyses with nonlinear springs, in contrast with the rest of the industry. There is further room to improve on the quality of communication and interaction between structural and geotechnical engineers. A lack of specific guidance on when SSI should be considered was reported, alongside broader training issues to ensure that structural and geotechnical engineers fundamentally understand the requirements and input/output needs of each role.

Directors’ Diversity and the Economic Value of Equity

The paper examines the effect of directors’ demographic and cognitive diversity on the economic value of equity based on longitudinal data from the top 15 Deposit Money Banks (DMBs) in Nigeria. The study finds steadily robust evidence that shows foreign and female directors at critical mass representation positively influence banks’ net worth (a proxy of the economic value of equity). Contrary to the hypothesis, the result of cognitive diversity was rather inconclusive due to the diverse direction of causality. While the effect of directors with Bachelor of Law degrees and industry experience shows a significant negative effect, the impact of directors with business-related degrees though positively linked to the economic value of equity but remained statistically insignificant. With average sampled directors having over 23 years of industry experience, the study concluded that excessive industry knowledge is injurious to financial performance. This is because these directors are perhaps more cautious about their reputation and thus are likely to exhibit diminishing marginal utility for wealth maximization.

An assessment of green logistics and environmental sustainability: Evidence from Bauchi

This study examines the impact of green logistics initiatives on environmental sustainability in Bauchi Metropolis - a state in the North East region of Nigeria. A survey method employing a questionnaire was used to collect data for the period of May to July 2022. A stratified snowball sampling technique was used to administer the questionnaire. Out of the 217 questionnaires administered, 197 were retrieved coded and analyzed using descriptive statistics, chi-square and regression. The result revealed that 2/3 of logistics managers are aware of how logistics activities negatively affect the environment, but only about 1/5 of them have taken steps toward green logistics initiatives. The result further showed that the categories of logistical operations and years of industry experience had a direct impact on most indicators of green logistics initiatives and sustainability. Moreover, the result showed that the adoption of green logistics initiatives depends on the amount of experience and categories of logistics. Since 1/3 of logistics managers are not aware of the environmental effect of logistics activities, the implication is that to implement green logistic policies, government needs to work with the most experienced logistics enterprises, particularly those in transport and storage.

Medhat M. Kamal 2023 SPE President

Medhat (Med) M. Kamal Medhat (Med) M. Kamal is a Chevron Fellow Emeritus and an Honorary Member of SPE. He previously worked for Cairo University, Amoco Production Company, Flopetrol Schlumberger, and ARCO Exploration and Production Company. Kamal has more than 45 years of industry experience in well testing, reservoir description, and production and reservoir engineering. He was an SPE Distinguished Lecturer in 1997–1998 and 2018–2019 during which he presented his lectures more than 80 times in 35 countries. He served as a member and chairman of SPE Annual Meeting Well Testing subcommittee and textbook and monograph committees, and as executive editor, associate editor, and technical reviewer for SPE Reservoir Evaluation & Engineering and the Journal of Petroleum Technology. He chaired the first SPE conference on research and development in 2007 and the Western Regional Meeting (2019). He served on the boards of directors of Mid-Continent, Gulf Coast, Dallas, and Golden Gate sections of SPE and chaired the Dallas and Golden Gate sections. He also served on the SPE International Board of Directors (2007–2009) as the Regional Director of Western North America. Kamal has been recognized with several regional and international awards including the SPE Cedric K. Ferguson Medal, SPE Formation Evaluation Award, SPE Distinguished Service Award, SPE North and East Texas Regional Service Award, and the Texas Petroleum Engineer of the Year Award. He holds a BSc in petroleum engineering and an MSc in engineering from Cairo University and an MS and PhD in petroleum engineering with a minor in computer science from Stanford University. Let’s begin with a brief introduction of the theme you’ve selected for your presidency, Petroleum++. What will you be emphasizing? There are three elements to this theme: petroleum, the first plus, and the second plus. Let me explain them one at a time. “Petroleum” refers to the challenges petroleum engineers face now and for the foreseeable future to provide the world with the hydrocarbon energy it needs. By hydrocarbons, I mean oil and natural gas, not coal. We can think of the entities that study and predict the world’s future need for energy as three groups: the government entities like the US Energy Information Administration (EIA) and the European Union International Energy Agency (IEA); the major international operators like ExxonMobil, Shell, etc.; and the national oil companies. The predictions provided by all three groups indicate the oil and natural gas share in the energy mix may decline slightly from a little over 50% currently to a little below 50% by 2050. However, the needed volume of hydrocarbons will increase as the world population moves from around 8 billion now to about 9.8 billion in 30 years and as the standard of living continues to improve in the developing regions such as Africa and Asia. When we look at the world’s current reserves and the current technology to produce these, you can add things up and see that we must continue our technical advancements to meet the growing demand for energy.

REVIVING THE KLANG VALLEY ECONOMY DURING PANDEMIC THROUGH DIGITALISATION OF THE MARITIME LOGISTICS INDUSTRY

The maritime logistics industry is an international business ecosystem and backbone of Malaysia’s economic development. Due to the COVID-19 pandemic, we have witnessed a drastic decline of industries all over the world, which may take a very long time to recover. This paper discusses the digital transformation of the maritime logistics industry based in the Klang Valley of Peninsular Malaysia as a strategic plan to improve existing business processes and make it resilient in face of the challenges brought on by the pandemic. We evaluated the digitalisation practices of maritime logistics companies to identify enablers that can help restore the economy as the industry tries to move on under the shadow of COVID-19. The Fuzzy Delphi (FD) method is used to collect and analyse data based on the response of 18 experts with more than five years of industry experience. A total of 15 key enablers were determined and ranked in terms of priority, with the top three being changes in the long-term industry growth rate, marketing innovation and implementation of digital platforms. These key enablers may then be used to develop good strategies to enhance competitiveness and build the resilience of this sector against the disruptions brought on by the pandemic.

Electrostatic charging phenomena on material web electro field meter measurements in a production machine and their interpretation

After many years of industrial experience and investigation of various fires in web-fed presses, it became clear that there is no generally valid explanation for the phenomenon of electrostatic charging of high-speed material webs (e.g., paper, film, composites). The first measurement results and their interpretation are presented for discussion. The measurements with an electro field meter have shown that after a rubber roller there are strong variations of the E-field at constant distance in a very short time which are shown i.e. in Fig. 8.Various studies on the interpretation of electrostatic charge phenomena on material webs, particularly regarding high separation speeds (currently up to more than 30 m/s), have shown that in the conventional manner, i.e., with the classical theory of Helmholtz double layers, not all electrostatic problems can be satisfactorily explained or predicted. From the potential hazards of high charged material webs, suggestions for the placement of ionizers are defined. This paper is intended as a stimulus for further research into the electrostatic processes at work in the processing of material web.

COVID-19 vaccine approvals: key lessons for mRNA therapeutics

The development of mRNA therapeutics is not a new phenomenon, but the key role played by mRNA-based vaccines in battling the COVID-19 pandemic has resulted a rapid acceleration in the development timeframe of this technology field. In a recent expert roundtable discussion, we spoke to a panel of experts within the field to better understand what lessons the vaccine and therapeutic fields can learn from each other. Here, we sum up some of their key thoughts. <div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/544f55bceea342b7b14d37488e0dc915.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name" style="color:#5D538A;">Venkata Indurthi</h3><h5 class="author-title" style="color:#5D538A;">Vice President Research and Development, Aldevron</h5><p class="focus-visible" data-focus-visible-added="">Venkata SK Indurthi, PhD is the Vice President of research and development at Aldevron (est. 1998, www.aldevron.com), a biologicals CDMO with sites in Fargo ND and Madison WI. He received his bachelor’s in engineering in biotechnology from SRM university (Chennai, India) and his Ph.D. in Pharmaceutical Sciences from North Dakota State University (Fargo, ND). After completing graduate school, he joined Aldevron as an assay development scientist and was focused developing assay for GMP release for biologics (DNA, RNA and protein). He then transitioned to a role of senior scientist, Product and Process Design (PPD) where he led the development of Aldervon’s mRNA process and platform and more recently as the Director of R&amp;D where he established all the R&amp;D efforts for Aldevron. Dr. Indurthi leads efforts that to develop new platforms and innovative manufacturing processes for the company including (not limiting to) the mRNA platform, plasmid DNA, gene synthesis and cell free synthetic DNA platform. His team also focuses on the development of new products for the company such as enzymes with improved attributes (increased yield, stability or activity). Dr. Indurthi’s research interests focus on the development of biologics. Particularly, new platform development from idea conception to commercialization. He has developed processes that are currently used for GMP manufacturing. Dr. Indurthi is also the operational head for the Aldevron RNA services. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/4d1901ea5f7e4906a920be4245fc9039.jpeg" data-image="1"></div><div class="author-det"><h3 class="author-name" style="color:#007589;">Joseph Barberio</h3><h5 class="author-title" style="color:#007589;">Director, Process Development, Strand Therapeutics Inc.</h5> Joseph Barberio is a biochemist and molecular biologist with a proven track record of solving complex problems with innovative solutions. He is the Director of mRNA Process Development at Strand Therapeutics and oversees Strand’s manufacturing strategy to support clinical development. With over fifteen years of industry experience, Joe specializes in process and analytical development and has extensive expertise in manufacturing of both viral and RNA based gene therapy medicinal products. The majority of Joseph’s career has been focused on building platforms for small biotech organizations. Most recently at bluebird bio, he constructed and led the mRNA process development team, a group designed to enable gene editing programs. Earlier in his career, Joe held process development roles at Moderna, Percivia, and Acceleron Pharma. In addition to his work at Strand, Joseph also serves on the Board of Directors of Sophie’s Hope Foundation, a non-profit charity supporting research for glycogen storage disease type 1b (GSD1b). </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/276f2895701f4c2e939bb8cc42991fec.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name" style="color:#00A795;">Scott Zobbi</h3><h5 class="author-title" style="color:#00A795;">Senior Business Development Manager, Custom POROS Chromatography Resins, Thermo Fisher Scientific</h5> Scott Zobbi is a Senior Manager of Business Development for Custom POROS Resins within the Bioproduction Division at Thermo Fisher Scientific. Scott has a B.S. in Biology from University of Connecticut and an MBA from the University of Massachusetts. Scott has worked on chromatography applications in the biotech industry for decades with 22 years spent at Thermo Fisher Scientific. His expertise is finding solutions to complex separation challenges draws on his experience in cGMP manufacturing, process development, customer training, sales and product management. In his current role, Scott is responsible for managing globally the Custom POROS Resin program, including working with customers to identify needs, in-house R&amp;D to develop solutions, and POROS manufacturing to commercialize bioprocess resins for GMP applications. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/7f8ed4c095f842d490465df72352b91a.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name" style="color: rgb(255, 127, 63);">Dr Christoph Kröner</h3><h5 class="author-title" style="color: rgb(255, 127, 63);">Director, DNA Process Development &amp; Cap Technology, BioNTech SE</h5> Christoph Kröner works as Director DNA Process Development &amp; Cap Technology at BioNTech RNA Pharmaceuticals GmbH with strong focus on developmental work for BioNTech’s various clinical projects using mRNA as drug substance. He has more than 10 years of experience working with nucleic acids like mRNAs. His work focused on mRNA-based therapeutics when he joined BioNTech in 2014 as a scientist. Christoph Kröner holds a diploma and PhD in chemistry from the University of Stuttgart, Germany. </div></div></div>

Critical success factors for tomorrow’s cellular immunotherapies

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://bioinsights.blob.core.windows.net/uploads/C-Quell-66 (2) copy.jpg" data-image="1"></div><div class="author-det"> <b>Bernd Schmidt</b> serves as Vice President, Product Delivery at Quell Therapeutics and has 20 years of industry experience in the pharmaceutical sector, covering a broad range of innovative medicines at different stages in development and post launch. He joined Quell from GSK where he served as MPD Leader with overall accountability for the CMC development, governance and end to end supply chain of a portfolio of medicines (small molecules and cell &amp; gene therapies) covering pre-clinical to late-phase development as well as commercial supply, incl. interactions with regulatory bodies. Prior to that he was the Technical Director and a member of the site leadership team of one of GSK’s main manufacturing facilities in the UK. Before re-joining GSK in 2012 he held roles of increasing responsibility in process and product development at AstraZeneca. </div></div></div>

A question of control? Next steps for novel TIL therapeutics

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Jan.jpeg" data-image="1"></div><div class="author-det"> <b>Jan ter Meulen</b> is a biotech executive (MD, PhD Virology, Board Certified Clin Microbiologist, Diploma Trop Med) with broad experience in immuno-oncology, vaccines, recombinant antibodies and infectious disease R&amp;D, from discovery through phase II clinical trials. He has 16 years of industry experience in leadership positions, including 11 years at biotech companies (CSO at Immune Design Corp. and Executive Director at Crucell Holland NV) and 5 years in pharma (Executive Director &amp; Head of Vaccine Basic Research Department at Merck &amp; Co.). He has conducted extensive cross-functional work in the field of antibodies and vaccines, including discovery research, preclinical development, process development, clinical development, regulatory affairs, and business development. Jan was recipient of a 5-year Howard Hughes International Research Scholarship, and has been a reviewer/consultant for the NIH, European Commission, German Ministry of Science and Education, French Research Agency, Medical Research Council UK, and South Africa. </div></div></div>

A framework for a hydrogen economy

Arun Majumdar is the Jay Precourt Professor at Stanford University, a faculty in the Department of Mechanical Engineering, and a Senior Fellow and former Director of the Precourt Institute for Energy. He served in the Obama administration as the Founding Director of the US Department of Energy's Advanced Research Projects Agency-Energy (ARPA-E) (2009–2012), as the Acting Undersecretary for Energy (2011–2012), and as the Vice Chair of the Secretary of Energy Advisory Board (2014–2017). Dr. Majumdar is a member of the US National Academy of Sciences, US National Academy of Engineering, and the American Academy of Arts and Sciences. John Deutch is an emeritus Institute Professor at MIT. He has served as Chairman of the Department of Chemistry, Dean of Science, and Provost. In the Carter administration, he served as Director of Energy Research (1977–1979), Acting Assistant Secretary for Energy Technology (1979), and Undersecretary (1979–1980) in the US Department of Energy. He has been a member of the President's Nuclear Safety Oversight Committee (1980–1981), the White House Science Council (1985–1989), the President's Committee of Advisors on Science and Technology (1997–2001), and the Secretary of the Energy Advisory Board (2008–2017). He has published widely on the technical and policy aspects of energy and the environment. Ravi Prasher is an Adjunct Professor at the University of California, Berkeley. He has more than 20 years of experience in working in R&D in large industry, startup, government, and academia. He was one of the first program directors at ARPA-E in the US Department of Energy. Prasher has published more than 100 papers on thermal energy science and technology and holds more than 30 patents. At UC Berkeley, he teaches undergraduate and graduate courses on thermal science and supervises multiple PhD students on various research topics, including thermochemical production of carbon-free hydrogen. Tom Griffin specializes in identifying high-impact technology investment opportunities in the manufacturing sector for Breakthrough Energy Ventures. He has over 25 years of industrial experience in applied technology development and deployment, including contributions over a wide range of energy and environmental sectors. He served as CTO at both Edeniq and Pennsylvania Sustainable Technologies (where was also co-founder), pursuing capabilities and applications in biofuels and catalytic fuel upgrading. Griffin was an officer in the US Nuclear Navy, directing operations of shipboard propulsion facilities. He holds SB, SM, and PhD degrees in Chemical Engineering from MIT and has authored or co-authored several granted patents.

Modern Asset Management

In this article we describe the current state of the asset management industry, what defines a modern asset manager and what prerequisites he needs to be successful. After all, the asset management industry has been facing fundamental challenges for years, which we will explain in detail. In doing so, we break away from the classic questions and show which points are really at stake. Technology, new data sources and artificial intelligence are changing the asset management industry for the better. Further success factors for the future are a modern work culture and clear and simple communication. We explain the five points in detail. They offer the ideal opportunity for a start-up to lead the modernization of the asset management industry. Four pillars are the prerequisite for a successful implementation: a combination of financial know-how, statistical and computer science know-how as well as many years of industry experience. We explain the reasons using an example.

Great educators in computer networking

This interview is part of a series on Great Educators in Computer Networking, where we interview some of the most impactful and skilled educators in our field. Here, we interviewed Australian Bruce Davie, the self-described computer scientist/engineer/runner/cyclist, who agreed to talk to us about his thoughts on computer networking education, his role in it, his thoughts about the big ideas in our field, and how the pandemic is changing our work. Bruce has over 30 years of industry experience and is well known for a broad spectrum of educational initiatives such as co-authoring several textbooks, as well as his contributions to many networking standards and technologies, including IP quality of service, network virtualization, software defined networking, and more

Managing raw and starting materials for viral vector manufacture: managing risk and staying flexible

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Eric Hacherlsq.jpg" data-image="1"></div><div class="author-det"> Eric Hacherl holds a PhD in Chemical Engineering from Rutgers University. As the Head of Manufacturing, he is responsible for Internal and External Manufacturing, Materials Management, Shipping &amp; Receiving and Manufacturing Science &amp; Technology. Eric joined Spark in September 2020 with over 20 years of experience in the pharmaceutical industry. His functional expertise lies in Operations, Supply Chain and Manufacturing Science &amp; Technology. His focus has been primarily on vaccines and large molecule manufacturing. Prior to joining Spark, he was the Site General Manager and VP of Operations for Catalent Gene Therapy in Baltimore, MD. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Klem photo 200x200.jpg" data-image="1"></div><div class="author-det"> Christopher Klem is an experienced professional specializing in technical and logistical oversight of external/contract manufacturing operations in the emerging gene therapy space. Effectively managed external manufacturing projects for over 15 years, specializing in relationship building and execution of program deliverables. Current experience in oversight of all aspects of outsourced supply chain partnerships: drug substance, drug product, secondary packaging and specialty distribution of commercial and clinical gene therapy products. Also have managed and directed internal Primary and Secondary operations in both pharmaceutical and biopharmaceutical manufacturing, directing large multi-tiered teams to meet internal manufacturing objectives. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Galbraith photo 200x200.jpg" data-image="1"></div><div class="author-det"> Mark Galbraith has worked in the biopharmaceutical industry for 20 years, where he has gained diverse experience and knowledge in all phases of product development from preclinical to commercial. Mark began his career at Merck &amp; Co, where he held positions of increasing responsibility in several functional areas related to vaccine clinical development and vaccine commercial manufacturing including analytical R&amp;D, regulatory sciences, commercial analytical support, and quality control operations. Mark continued to develop his career in quality control management and analytical development by directing the quality control activities at Celldex Therapeutics, Bristol Myers-Squibb, and Gilead Sciences. Mark has gained a broad knowledge of vaccines, biotechnology products, sterile pharmaceuticals, and now gene therapy. Mark is currently serving as Head of Quality Control and Analytical Sciences for Spark Therapeutics Inc. in Philadelphia, PA. Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Ryan Bartock sq.jpg" data-image="1"></div><div class="author-det"> Ryan Bartock is Vice President and Head of Technical Strategy &amp; Operations at Spark Therapeutics, a fully integrated gene therapy company and member of the Roche family of companies. Ryan joined Spark Therapeutics as Head of Supply Chain and Network Strategy in 2017 where he established the Supply Chain function and launched the first ever FDA approved Gene therapy. His current responsibilities include leading the Supply Chain and CMC Program Management functions, as well as strategic initiatives across Research, Technical and Commercial organizations. He is also interim Head of Technical Development, overseeing Process and Analytical development, Automation and Pre-Clinical Operations. Ryan holds BSc in Engineering and Business from Drexel University. His 18 years of industry experience spans pre-clinical and clinical development, manufacturing operations, supply chain, CMC, corporate strategy and new product launches at both GSK and Merck. </div></div></div>

Viral vector production process intensification: analytics, automation, in-line testing and more

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/888145b9bcb9494d9523fe80a135ed5f.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name">Susan D’Costa</h3><h5 class="author-title">Senior Director, Technical Program Design, Viral Vector Services, Thermo Fisher Scientific</h5> In her current role, Susan functions as SME for VVS’ viral vector manufacturing platforms and systems providing scientific and technical input for customer programs. Prior to this role, she served as the Head of Process and Analytical Development at Viral Vector Services, Thermo Fisher Scientific, formerly Brammer Bio for over three years. In her role as head of PD/ADA, she provided critical scientific input for projects developed and manufactured at VVS. She has built a robust team for the development, customization, optimization, scale-up and tech transfer of gene therapy vector process and analytics. Susan was also integral to developing robust QC analytics for incoming starting and raw materials and for the release of the clinical vector products in her role as Director of Quality Control at Brammer Bio/Florida Biologix. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/1b65fe190645414eb14a9f6b56f12cbf.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name">Mike Delahaye</h3><h5 class="author-title">Head of Viral Vector Industrialisation, Cell and Gene Therapy Catapult</h5> Michael has almost 15 years of industrial experience within the cell and gene therapy sector. He leads a team of experienced scientists within the Viral Gene Delivery programme, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&amp;D operations. The team’s key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterisation tools to facilitate the production of AAV based gene therapies. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/f89a9bee7b7f422f90e20f14ed51c093.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name">Michael White</h3><h5 class="author-title">Senior Scientist, ‎Affinia Therapeutics</h5> Michael is the Head of Viral Vector Industrialisation at the Cell and Gene Therapy Catapult and has almost 15 years of industrial experience within the cell and gene therapy sector. He leads a team of experienced scientists within the Viral Gene Delivery programme, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&amp;D operations. The team’s key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterisation tools to facilitate the production of AAV based gene therapies. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/776b16a7bc2e4fbfbe681c777fe42fcd.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name">Franz Gerner</h3><h5 class="author-title">Vice President, Technical Operations, Sio Gene Therapies</h5> Franz Gerner is responsible for process development, manufacturing and analytical activities, including overseeing outsourced activities at CDMOs and CTOs. Prior to joining Sio Gene Therapies, Franz worked at Regenxbio, joining the company at an early stage and building up the Process Development team over the course of 5 years. He started to work in the AAV gene therapy field about 25 years ago. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/c0e2ab70fb724206bfe9ddbb85d6b59f.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name">Jessica Tate</h3><h5 class="author-title">Head of Science &amp; Technology Development, Viral Vector Services, Thermo Fisher Scientific</h5> Jessica Tate has spent the last 15 years producing, purifying, and characterizing various virus modalities, in a combination of industry and academic environments. Currently she leads Thermo Fisher Scientific’s Viral Vector Science and Technology team, who’s mission is to develop and/or employ novel state-of-the-art technologies in the manufacturing of viral vector gene therapies. </div></div></div><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/23d387b3f3674a78b57c369bcbcdf517.jpg" data-image="1"></div><div class="author-det"><h3 class="author-name">Jim Warren</h3><h5 class="author-title">Vice President, Pharmaceutical Development, Ultragenyx Pharmaceutical Inc.</h5> Dr. Warren has 27 years of experience in the pharmaceutical and biotechnology industry. At Ultragenyx, he leads a team of over 60 scientists and engineers, responsible for all early and late stage Process and Analytical Development of viral vector gene therapy products as well as Pilot Scale Manufacturing in the Woburn, MA Pilot Plant. Before coming to Ultragenyx Jim held senior CMC leadership positions at Homology Medicines, bluebird bio, and Shire. Earlier in his career, Jim spent 16 years at Merck &amp; Co., Inc., where he led process development, technology transfer, and manufacturing sciences teams responsible for development of several clinical vector and vaccine candidates and the licensure of multiple commercial vaccines (RotaTeq®, Varivax®, ProQuad®, and Zostavax®). </div></div></div>

You Do Belong! Transformative Black Women Faculty Recommendations for Broadening Participation in US P-20 Computing Education

 &#x0D;  This study aimed to amplify Black women faculty’s recommendations for broadening participation of the next generation of Black girls and women as they matriculate from primary school into advanced graduate degrees (P-20) in computing education (CE). As tenure-track faculty, these transformative women have attained the highest degree (i.e., Ph.D.) in postsecondary CE in the United States (US). To govern the knowledge validation process, I utilized Afrocentric feminist epistemology undergirded by critical race theory and Black feminist thought. Upon conducting thematic analysis, I identified four emergent themes to broaden participation of Black girls and women in computing: 1) improve access, quality, and early exposure to CE, 2) create equitable and equal spaces for Black girls and women, 3) confront unconscious biases of teachers and faculty, and 4) provide mentoring opportunities. As an emerging Black woman scholar, with a bachelor’s degree in computer science and 15 years of industry experience, I had a “unique angle of vision” to interpret and inform this study’s findings. This study builds upon limited knowledge about interventions needed to support Black girls and women in US P-20 computing education. 

Mining Design Heuristics for Additive Manufacturing Via Eye-Tracking Methods and Hidden Markov Modeling

Abstract In this research, we collected eye-tracking data from nine engineering graduate students as they redesigned a traditionally manufactured part for additive manufacturing (AM). Final artifacts were assessed for manufacturability and quality of final design, and design behaviors were captured via the eye-tracking data. Statistical analysis of design behavior duration shows that participants with more than 3 years of industry experience spend significantly less time removing material and revising than those with less experience. Hidden Markov modeling (HMM) analysis of the design behaviors gives insight to the transitions between behaviors through which designers proceed. Findings show that high-performing designers proceeded through four behavioral states, smoothly transitioning between states. In contrast, low-performing designers roughly transitioned between states, with moderate transition probabilities back and forth between multiple states.